PURPOSE: To assess whether radiation treatment modality with proton beam therapy (PBT) or intensity-modulated radiation therapy (IMRT) is associated with lymphopenia in patients treated with definitive chemoradiation for esophageal cancer. METHODS AND MATERIALS: Patients with esophageal cancer treated with bimodality therapy (n = 448) between 2004 and 2016 were retrospectively reviewed. Patients treated with PBT were matched by propensity score with those treated with IMRT, based on key patient and disease factors, and stratified by clinical disease stage. Patients who developed early, distant metastatic disease within 1 month of completing radiation were excluded. Univariable and multivariable logistic regression were used to identify variables associated with increased risk of grade 4 lymphopenia. Multivariable Cox proportional hazards regression was used to assess factors associated with overall survival, disease-free survival, and locoregional relapse-free survival. RESULTS: Patients who had IMRT and PBT matched by propensity score (n = 220) were not different with respect to age, sex, stage, performance status, tumor location, histology, tumor target volume, or induction chemotherapy. Treatment with IMRT, compared with PBT (odds ratio [OR], 2.13; 95% confidence interval [95% CI], 1.19-3.81; P = .01), increased age (OR, 1.039/y increase; 95% CI, 1.003-1.076; P = .03), and greater planning target volume (OR, 3.47 per 1-unit increase in log (planning target volume); 95% CI, 1.67-7.21; P < .001), was associated with increased risk of grade 4 lymphopenia. Radiation modality was associated with lymphocyte reduction in patients with tumors in the lower esophagus (P = .005) but not for those with tumors in the upper or middle esophagus (P = 0.32). CONCLUSIONS: In patients with esophageal cancer treated with definitive chemoradiation, PBT reduces the risk of severe, treatment-related lymphopenia, particularly in tumors of the lower esophagus.
PURPOSE: To assess whether radiation treatment modality with proton beam therapy (PBT) or intensity-modulated radiation therapy (IMRT) is associated with lymphopenia in patients treated with definitive chemoradiation for esophageal cancer. METHODS AND MATERIALS: Patients with esophageal cancer treated with bimodality therapy (n = 448) between 2004 and 2016 were retrospectively reviewed. Patients treated with PBT were matched by propensity score with those treated with IMRT, based on key patient and disease factors, and stratified by clinical disease stage. Patients who developed early, distant metastatic disease within 1 month of completing radiation were excluded. Univariable and multivariable logistic regression were used to identify variables associated with increased risk of grade 4 lymphopenia. Multivariable Cox proportional hazards regression was used to assess factors associated with overall survival, disease-free survival, and locoregional relapse-free survival. RESULTS: Patients who had IMRT and PBT matched by propensity score (n = 220) were not different with respect to age, sex, stage, performance status, tumor location, histology, tumor target volume, or induction chemotherapy. Treatment with IMRT, compared with PBT (odds ratio [OR], 2.13; 95% confidence interval [95% CI], 1.19-3.81; P = .01), increased age (OR, 1.039/y increase; 95% CI, 1.003-1.076; P = .03), and greater planning target volume (OR, 3.47 per 1-unit increase in log (planning target volume); 95% CI, 1.67-7.21; P < .001), was associated with increased risk of grade 4 lymphopenia. Radiation modality was associated with lymphocyte reduction in patients with tumors in the lower esophagus (P = .005) but not for those with tumors in the upper or middle esophagus (P = 0.32). CONCLUSIONS: In patients with esophageal cancer treated with definitive chemoradiation, PBT reduces the risk of severe, treatment-related lymphopenia, particularly in tumors of the lower esophagus.
Authors: Stephen G Swisher; Jennifer Moughan; Ritsuko U Komaki; Jaffer A Ajani; Tsung T Wu; Wayne L Hofstetter; Andre A Konski; Christopher G Willett Journal: J Thorac Oncol Date: 2016-10-08 Impact factor: 15.609
Authors: Aaron T Wild; Joseph M Herman; Avani S Dholakia; Shalini Moningi; Yao Lu; Lauren M Rosati; Amy Hacker-Prietz; Ryan K Assadi; Ali M Saeed; Timothy M Pawlik; Elizabeth M Jaffee; Daniel A Laheru; Phuoc T Tran; Matthew J Weiss; Christopher L Wolfgang; Eric Ford; Stuart A Grossman; Xiaobu Ye; Susannah G Ellsworth Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-01 Impact factor: 7.038
Authors: Aaron T Wild; Xiaobu Ye; Susannah G Ellsworth; Jessica A Smith; Amol K Narang; Tanu Garg; Jian Campian; Daniel A Laheru; Lei Zheng; Christopher L Wolfgang; Phuoc T Tran; Stuart A Grossman; Joseph M Herman Journal: Am J Clin Oncol Date: 2015-06 Impact factor: 2.339
Authors: Steven H Lin; Brian P Hobbs; Vivek Verma; Rebecca S Tidwell; Grace L Smith; Xiudong Lei; Erin M Corsini; Isabel Mok; Xiong Wei; Luyang Yao; Xin Wang; Ritsuko U Komaki; Joe Y Chang; Stephen G Chun; Melenda D Jeter; Stephen G Swisher; Jaffer A Ajani; Mariela Blum-Murphy; Ara A Vaporciyan; Reza J Mehran; Albert C Koong; Saumil J Gandhi; Wayne L Hofstetter; Theodore S Hong; Thomas F Delaney; Zhongxing Liao; Radhe Mohan Journal: J Clin Oncol Date: 2020-03-11 Impact factor: 44.544
Authors: Cai Xu; Jian-Yue Jin; Ming Zhang; Amy Liu; Jun Wang; Radhe Mohan; Fengming Spring Kong; Steven H Lin Journal: Radiother Oncol Date: 2020-03-19 Impact factor: 6.280
Authors: Alice Y Ho; Jean L Wright; Rachel C Blitzblau; Robert W Mutter; Dan G Duda; Larry Norton; Aditya Bardia; Laura Spring; Steven J Isakoff; Jonathan H Chen; Clemens Grassberger; Jennifer R Bellon; Sushil Beriwal; Atif J Khan; Corey Speers; Samantha A Dunn; Alastair Thompson; Cesar A Santa-Maria; Ian E Krop; Elizabeth Mittendorf; Tari A King; Gaorav P Gupta Journal: Int J Radiat Oncol Biol Phys Date: 2020-05-14 Impact factor: 7.038
Authors: Shu Xing; Jungwook Shin; Jennifer Pursley; Camilo M Correa-Alfonso; Nicolas Depauw; Sean Domal; Julia Withrow; Wesley Bolch; Clemens Grassberger; Harald Paganetti Journal: Phys Med Biol Date: 2022-02-15 Impact factor: 3.609
Authors: Cristina M DeCesaris; Melanie Berger; J Isabelle Choi; Shamus R Carr; Whitney M Burrows; William F Regine; Charles B Simone; Jason K Molitoris Journal: J Gastrointest Oncol Date: 2020-08